Business, energy, technology, markets and global industry news from Business News Today

organ rejection

PharmaDeviceNews organ rejection
Representative image: Natera’s Prospera kidney transplant monitoring test will support Eledon Pharmaceuticals’ planned Phase 3 tegoprubart trial, highlighting the growing role of donor-derived cell-free DNA in detecting graft injury and strengthening transplant surveillance.
Medical Devices & Diagnostics

Why Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3

Natera’s Prospera assay will provide serial molecular graft surveillance in Eledon’s planned Phase 3 tegoprubart study, creating a major test of how diagnostics can strengthen transplant drug development.

Read More
Representative image of pharmaceutical quality control and drug manufacturing, reflecting Concord Biotech’s United States Food and Drug Administration approval for Mycophenolate Mofetil oral suspension and the market focus on its transplant immunosuppressant portfolio.
Pharma & Biotech

Can Mycophenolate Mofetil approval strengthen Concord Biotech’s United States generics strategy?

Find out how Concord Biotech’s FDA approval for Mycophenolate Mofetil could reshape its transplant generics strategy.

Read More
Pharma & Biotech

Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?

Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.

Read More